Suzhou Hycan Holdings (002787.SZ) has announced an expected increase, with a net profit of 70 million to 80 million yuan for the year 2024, representing a growth of 730.26% to 848.87%.
(002787.SZ) released the performance forecast for the year 2024, expecting the full year attributable to the shareholders of the listed company...
Suzhou Hycan Holdings (002787.SZ) announced its performance forecast for the year 2024, expecting a net profit attributable to shareholders of the listed company of 70 million to 80 million yuan, a year-on-year increase of 730.26% to 848.87%.
During the reporting period, the company faced challenges in the intensified industry competition, but actively expanded domestic and foreign markets, explored customer needs, and continued to promote lean management. Through measures such as process optimization and improvement, the company improved production efficiency. Compared with the same period last year, the company's operating income, gross profit margin, and profit all achieved growth.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.

RECOMMEND

General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025

Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025

Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025